Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

查看全文 作　　者：Caicun;Zhou;Yi-Long;Wu;Gongyan;Chen;Jifeng;Feng;Xiao-Qing;Liu;Changli;Wang;Shucai;Zhang;Jie;Wang;Songwen;Zhou;Shengxiang;Ren;Shun;Lu;Li;Zhang;Chengping;Hu;Chunhong;Hu;Yi;Luo;Lei;Chen;Ming;Ye;Jianan;Huang;Xiuyi;Zhi;Yiping;Zhang;Qingyu;Xiu;Jun;Ma;Li;Zhang;C